下一代微封装技术用于益生菌保护和精确传递.
Yixin Zhu1, Longxian Lv2, Bingbing Du1
1Jinan Microecological Biomedicine Shandong Laboratory, Jinan, Shandong, China.
Microbial biotechnology
|February 18, 2026
概括
微封装在口服时保护有益的益生菌,提高它们的生存率和治疗疗效. 本综述探讨了改善益生菌稳定性和向性输送的先进技术.
科学领域:
- 微生物学 微生物学
- 生物技术是生物技术.
- 材料科学 材料科学 材料科学
背景情况:
- 益生菌提供健康益处,但与口服分娩的生存斗争.
- 胃酸,胆盐和肠道状况降低了益生菌的生存能力.
- 微封装提供了一种保护益生菌的解决方案.
研究的目的:
- 审查益生菌的先进的微封装材料和技术.
- 检查增强益生菌稳定性和有针对性的输送的战略.
- 评估工业应用的安全性和可扩展性.
主要方法:
- 关于微封装技术的综合文献综述.
- 对益生菌保护的材料和技术的分析.
- 评估先进的输送系统,如pH响应和针对炎症的微囊.
主要成果:
- 最先进的材料和技术显著提高了益生菌的稳定性.
- 先进的输送系统确保精确的肠道释放和殖民.
- 安全性和可扩展性挑战需要进一步调查.
结论:
- 下一代微封装有望为更安全,更有效的益生菌疗法提供希望.
- 生物相容材料和经济高效的生产对于可扩展性至关重要.
- 通过先进的传递系统,可以实现个性化的益生菌治疗.
相关概念视频
Microorganisms in Medicine and Therapeutics
1.2K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.2K
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
230
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
230
Modified-Release Drug Delivery Systems: Site-Targeted
29
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
29
Modified-Release Drug Delivery Systems: Overview
24
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
24
Site-Targeted Drug Delivery Systems: Polymeric Carriers
31
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
31
Oral Drug Delivery Systems: Delayed-Release Systems
41
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
41


